Nichols & Pratt Advisers LLP MA lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 156,025 shares of the biopharmaceutical company’s stock after selling 3,930 shares during the quarter. Nichols & Pratt Advisers LLP MA’s holdings in Gilead Sciences were worth $12,676,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of GILD. Sanders Capital LLC acquired a new position in Gilead Sciences in the third quarter valued at about $427,585,000. Renaissance Technologies LLC raised its stake in Gilead Sciences by 35.0% during the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Gilead Sciences by 84.7% during the third quarter. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company’s stock worth $446,197,000 after acquiring an additional 2,524,657 shares in the last quarter. Vanguard Group Inc. raised its stake in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Gilead Sciences by 50.0% during the second quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock worth $438,244,000 after acquiring an additional 2,062,886 shares in the last quarter. 75.95% of the stock is owned by institutional investors and hedge funds.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP James R. Meyers sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the transaction, the executive vice president now owns 102,715 shares in the company, valued at $8,241,851.60. The disclosure for this sale can be found here. Insiders have sold a total of 591,666 shares of company stock worth $44,466,567 over the last 90 days. Company insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.75 EPS. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.
Several research analysts have commented on the company. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Oppenheimer assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating for the company. Mizuho boosted their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Leerink Swann boosted their target price on Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research note on Thursday, October 5th. Finally, BMO Capital Markets lowered their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $85.53.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://weekherald.com/2018/01/20/nichols-pratt-advisers-llp-ma-has-12-68-million-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.